Amgen Inc, a prominent global biotechnology and pharmaceutical entity, disclosed a data security incident to the Indiana Attorney General on August 17, 2026. This breach, occurring on or around July 1, 2026, highlights the ongoing challenge companies face in protecting vast amounts of sensitive information entrusted to them, especially given Amgen's role in handling proprietary clinical trial data and extensive personal data for patients and trial participants.
According to the breach notice, the compromised data includes sensitive categories such as Full Name, Date of Birth, Social Security Number, Clinical Trial Participation Records, Medical History and Treatment Information, Health Insurance ID Number, Mailing Address, and Email Address. The exposure of this combination of personal identifiers and health-related data creates significant risks. Individuals could face potential medical identity theft, leading to fraudulent insurance claims or dangerous inaccuracies in their medical records, as well as financial identity theft, unauthorized account access, and sophisticated phishing attempts.
As a company operating within the healthcare ecosystem and handling protected personal and health information, Amgen Inc has strict legal obligations to implement robust security measures. This includes complying with various federal and state regulations, such as the Health Insurance Portability and Accountability Act (HIPAA) where applicable, which mandate strong safeguards to protect confidential data. The occurrence of this data breach suggests potential gaps or failures in these crucial security protocols.
Receiving a data breach notification letter from Amgen Inc confirms that your personal information was impacted by this incident. It's important to understand that you do not need to have already suffered financial loss or identity theft to pursue legal recourse; the mere compromise of your private data and the heightened risk of future harm may be sufficient under the law.
Our law firm is actively investigating the Amgen Inc data breach on behalf of individuals who received notification letters. If you received an official letter from Amgen regarding this incident, we encourage you to contact us for a free, no-obligation case review. We operate on a contingency fee basis, meaning there are no out-of-pocket costs or upfront legal fees, and we only receive payment if we successfully recover damages for you.